Victory Capital Management Inc. Has $13.07 Million Holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Victory Capital Management Inc. lifted its holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) by 1,358.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 118,375 shares of the biopharmaceutical company’s stock after purchasing an additional 110,260 shares during the period. Victory Capital Management Inc. owned 0.28% of Prometheus Biosciences worth $13,074,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Truist Financial Corp acquired a new stake in shares of Prometheus Biosciences in the 3rd quarter valued at $208,000. Fred Alger Management LLC lifted its stake in shares of Prometheus Biosciences by 325.5% in the 3rd quarter. Fred Alger Management LLC now owns 1,036,165 shares of the biopharmaceutical company’s stock valued at $61,144,000 after purchasing an additional 792,620 shares during the last quarter. Aigen Investment Management LP acquired a new stake in shares of Prometheus Biosciences in the 3rd quarter valued at $248,000. Quantamental Technologies LLC acquired a new position in Prometheus Biosciences during the 3rd quarter worth $283,000. Finally, SG Americas Securities LLC lifted its position in Prometheus Biosciences by 84.5% during the 4th quarter. SG Americas Securities LLC now owns 12,107 shares of the biopharmaceutical company’s stock worth $1,332,000 after acquiring an additional 5,544 shares during the last quarter. Institutional investors and hedge funds own 78.31% of the company’s stock.

Prometheus Biosciences Stock Performance

Shares of RXDX opened at $198.70 on Wednesday. The company has a 50-day simple moving average of $155.99 and a 200-day simple moving average of $118.22. Prometheus Biosciences, Inc. has a 52 week low of $22.31 and a 52 week high of $198.99. The company has a quick ratio of 37.56, a current ratio of 37.56 and a debt-to-equity ratio of 0.04.

Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.06. The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative return on equity of 33.50%. The company’s revenue was down 71.8% on a year-over-year basis. On average, equities research analysts forecast that Prometheus Biosciences, Inc. will post -3.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on RXDX. Credit Suisse Group lowered shares of Prometheus Biosciences from an “outperform” rating to a “neutral” rating in a research report on Monday, April 17th. Guggenheim lowered shares of Prometheus Biosciences from a “buy” rating to a “neutral” rating and cut their target price for the stock from $225.00 to $200.00 in a research report on Monday, April 17th. Wells Fargo & Company lowered shares of Prometheus Biosciences from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, April 18th. Stifel Nicolaus lowered shares of Prometheus Biosciences from a “buy” rating to a “hold” rating and boosted their target price for the stock from $155.00 to $200.00 in a research report on Sunday, April 16th. Finally, The Goldman Sachs Group boosted their target price on shares of Prometheus Biosciences from $117.00 to $144.00 and gave the stock a “buy” rating in a research report on Tuesday, January 31st. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $153.36.

Insider Activity at Prometheus Biosciences

In related news, CFO Keith W. Marshall sold 10,000 shares of the company’s stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $108.42, for a total value of $1,084,200.00. Following the sale, the chief financial officer now owns 9,811 shares of the company’s stock, valued at $1,063,708.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Prometheus Biosciences news, major shareholder Sinai Intellectual Prop Cedars sold 865,000 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $114.59, for a total transaction of $99,120,350.00. Following the sale, the insider now directly owns 4,001,132 shares of the company’s stock, valued at $458,489,715.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Keith W. Marshall sold 10,000 shares of the company’s stock in a transaction dated Wednesday, April 5th. The stock was sold at an average price of $108.42, for a total transaction of $1,084,200.00. Following the sale, the chief financial officer now directly owns 9,811 shares in the company, valued at $1,063,708.62. The disclosure for this sale can be found here. Insiders have sold a total of 921,320 shares of company stock valued at $105,745,913 over the last quarter. 3.40% of the stock is owned by company insiders.

About Prometheus Biosciences

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.